



## PHARMACY AND THERAPEUTICS COMMITTEE

DATE: February 10, 2022

LOCATION: Zoom Only

CALLED TO ORDER: 7:00 a.m.

ADJOURNED: 8:00 a.m.

Voting Member Attendance:		Non-Voting Member Attendance:		Guests:
X	Nathan Chamberlain, MD- Chairman	X	Matthew Kodsi, MD- Quality	Tina Mathew, Pharmacy Resident Doug Dertien, Pharmacy Resident Sabrina Curtis, Pharmacy Resident Jessica Duke, Pharmacy Resident
X	Mark Anderson, MD- Infectious Disease	X	Aditya Mandawat, MD- Cardiology	
X	Justin Blinn, MD- Anesthesiology	X	Daniel Marsh, PharmD- Director of Pharmacy	
X	David Dodson, MD- Hospitalist	X	Chad Paxson, MD- Intensivist	
X	Karen Frank, RN- Quality		Vimal Ramjee, MD- Cardiology	
	F. Lee Hamilton, MD- Hospitalist		James Wahl, MD- Hospitalist, GA	
X	William Haren, MD- Psychiatry		Richard Yap, MD- Hospitalist	
X	Rhonda Hatfield, RN-CNO			
		X	Karen Babb, PharmD- Manager	
			Jamie Barrie, PharmD- Manager, HX	
		X	Chris Chastain- Admin Coordinator	
		X	Kenneth Dyer, PharmD- Ops Manager	
		X	Rodney Elliott- Purchasing	
		X	Lori Hammon, RN- Quality	
		X	Shannon Harris, RN- Infection Prevention	
		X	Kevin Hopkins, RT- Director of Resp Therapy	
		X	Rachel Kile, PharmD- Clinical Manager	
		X	Farrah Reidt- Clinical Nutrition	
		X	Carey Smith, RPh- Manager, GA	

This meeting will be convened under the protection of the Tennessee Statute 63-6-219 and the Health Care Quality Improvement Act of 1986, Public Law 99-660. All information, case reviews, meeting minutes, statistics and correspondence are confidential and protected. Included in that protection are those that are involved in the review of the information. Any discussion of this information outside the realm of Peer Review constitutes a breach and violates the protection of the persons involved in the breach.

AGENDA ITEM	FINDINGS OR CONCLUSION	ACTION, RESPONSIBILITY	STATUS
<b>Minutes</b>	The December 2021 minutes were approved as submitted.	Approved	Complete
<b>CommonSpirit Health System P&amp;T Committee</b>	<b>January 2022 Decision Brief:</b> The medication decisions that were approved at the CommonSpirit Health System P&T committee meeting were reviewed. All new system formulary medications or changes were either consistent with existing CHI Memorial formulary decisions or are described in the "Formulary Decisions & Therapeutic Interchanges" section of the minutes below, or will be reviewed at an upcoming P&T committee meeting. Bezlotoxumab (Zinplava®) for the treatment of C. difficile infection is being reviewed by the Antimicrobial Stewardship Subcommittee before being brought to our P&T Committee.	Approved	Complete
<b>Formulary Decisions &amp; Therapeutic Interchanges</b>	<b>A. Remifentanil (Ultiva®):</b> Expansion of utilization criteria was requested to include all neurosurgical cases of the head in order to ensure fast wake up and quicker neurological assessment regardless if the patient is awake or asleep for the surgery. The committee approved revision of the current restriction criteria for remifentanil to the following: Ordering restricted to Anesthesia providers; craniotomies associated with very low associated post-op pain plus the need for rapid emergence and full neurological assessment; or awake fiberoptic intubations.	Approved	Complete
	<b>B. Insulin glargine (Semglee®):</b> Semglee (insulin glargine-yfgn) is a fully interchangeable biosimilar for the reference product, Lantus. Semglee will replace Lantus as the long-acting insulin product at CHI Memorial hospitals. The existing automatic therapeutic interchange for long acting insulins will	Approved	Complete



	<p>removal of argatroban (non-formulary); pharmacist ordering of INR every other day if the INR is stable; clarification of baseline labs to align with current orders; instructions for provider notification if labs cannot be drawn for heparin infusions; updated PCC dosing for DOAC reversal.</p> <p><b>B. Bradycardia Management Protocol:</b> A policy to support the previously approved protocol was adopted. The atropine dose was updated to 1 mg in alignment with 2020 ACLS guideline updates.</p> <p><b>C. Contrast Media Administration:</b> This policy was updated to remove Omnipaque from the product column of the diagnostic radiology protocol table since Omnipaque was previously removed from formulary.</p> <p><b>D. Drug and Food Interaction/Education:</b> The committee reviewed this policy per periodic review requirements. No updates were needed.</p> <p><b>E. Sedatives-Hypnotics for Sleep:</b> This policy was updated to include suvorexant (Belsomra®) to the automatic therapeutic interchange to Ambien 5 mg. Dr. Paxson suggested that the policy stating that no sedative/hypnotics for sleep be administered to any patient greater than 65 may be overly restrictive and recommended that it be re-reviewed separately. Per Lori, the current policy was based on a &gt;10 year old internal study on falls. Rhonda recommended a best practice review for sleep in hospitalized patients. Rachel will coordinate a small group to review the prior study and determine next steps.</p> <p><b>F. Respiratory Distress Protocol:</b> The committee reviewed this policy per annual protocol review requirements. No updates were needed.</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>Complete</p> <p>Complete</p> <p>Complete</p> <p>Complete</p>
<b>Nutrition</b>	<p><b>A. Nutrition Care Manual:</b> Farrah shared updates to the nutrition care manual which were reviewed by the committee.</p>	<p>Approved</p>	<p>Complete</p>

There being no further business, the meeting was adjourned at 8:00 a.m. The next P&T meeting is **April 7, 2022 @ 7:00 a.m.**

Respectfully submitted,  
Daniel Marsh, PharmD, Director of Pharmacy; Rachel Kile, PharmD, Pharmacy Clinical Manager

Approved by,  
Nathan Chamberlain, MD, Chairman